Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women

Clinical Pharmacokinetics

Volumn 51, Issue 12, 2012, Pages 809-822

  Dumond, Julie B ^a   Nicol, Melanie R ^a   Kendrick, Racheal N ^a   Garonzik, Samira M ^b   Patterson, Kristine B ^c   Cohen, Myron S ^c   Forrest, Alan ^b   Kashuba, Angela D M ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RITONAVIR; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS RNA;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG PENETRATION; DRUG PROTEIN BINDING; FEMALE; FEMALE GENITAL SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; POPULATION MODEL; PREMENOPAUSE; PRIORITY JOURNAL;

ADENINE; ADULT; ANTI-HIV AGENTS; BENZOXAZINES; FEMALE; GENITALIA, FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MODELS, BIOLOGICAL; OLIGOPEPTIDES; ORGANOPHOSPHONATES; PREMENOPAUSE; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84873462024     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-012-0012-y     Document Type: Article

References (41)

1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
2. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342:921-9.
3. Eron JJ Jr, Smeaton LM, Fiscus SA, Gulick RM, Currier JS, Lennox JL, et al. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS Clinical Trials Group Protocol 850). J Infect Dis. 2000;181:1622-8.
4. Cu-Uvin S, Caliendo AM, Reinert S, Chang A, Juliano-Remollino C, Flanigan TP, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS. 2000;14:415-21.
5. Launay O, Tod M, Tschöpe I, Si-Mohamed A, Bélarbi L, Charpentier C, et al. Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study. Antivir Ther. 2011;16:843-52.
6. Mitchell C, Hitti J, Paul K, Agnew K, Cohn SE, Luque AE, et al. Cervicovaginal shedding of HIV type 1 is related to genital tract inflammation independent of changes in vaginal microbiota. AIDS Res Hum Retroviruses. 2011;27:35-9.
7. Henning TR, Kissinger P, Lacour N, Meyaski-Schluter M, Clark R, Amedee AM. Elevated cervical white blood cell infiltrate is associated with genital HIV detection in a longitudinal cohort of antiretroviral therapy-adherent women. J Infect Dis. 2010;202:1543-52.
8. Lorello G, la Porte C, Pilon R, Zhang G, Karnauchow T, MacPherson P. Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma. HIV Med. 2009;10:548-54.
9. Kovacs A, Wasserman SS, Burns D, Wright DJ, Cohn J, Landay A, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet. 2001;358:1593.
10. Si-Mohamed A, Kazatchkine MD, Heard I, Goujon C, Prazuck T, Aymard G, et al. Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J Infect Dis. 2000;182:112-22.
11. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16:1149-67.
12. Nicol MR, Kashuba ADM. Pharmacologic opportunities for HIV prevention. Clin Pharmacol Ther. 2010;88:598-609.
13. Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, Rezk NL, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS. 2007;21:1899-907.
14. Bristol-Myers Squibb Company. Sustiva (efavirenz) full U.S. prescribing information. Princeton: Bristol-Myers Squibb Company; 2009.
15. Bristol-Myers Squibb Company. Reyataz (atazanavir) full U.S. prescribing information. Princeton: Bristol-Myers Squibb Company; 2009.
16. Gilead Sciences. Viread full U.S. prescribing information. Foster City: Gilead Sciences; 2012.
17. ViiV Healthcase/GlaxoSmithKline. Epivir full U.S. prescribing information. Research Triangle Park: ViiV Healthcase/GlaxoSmithKline; 2011.
18. Jung BH, Rezk NL, Bridges AS, Corbett AH, Kashuba ADM. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr. 2007;21:1095-104.
19. Rezk NL, Crutchley RD, Kashuba ADM. Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction. J Chromatogr B Anal Technol Biomed Life Sci. 2005;822:201-8.
20. Rezk NL, Tidwell RR, Kashuba ADM. Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Anal Technol Biomed Life Sci. 2003;791:137-47.
21. Rezk NL, Tidwell RR, Kashuba ADM. High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. J Chromatogr B Anal Technol Biomed Life Sci. 2004;805:241-7.
22. Rezk NLMS, Crutchley RD, Yeh RFP, Kashuba ADMP. Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring. Ther Drug Monit. 2006;28:517-25.
23. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles: Biomedical Simulations Resource; 2009.
24. D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed. 1979;9:115-34.
25. Beijnen JH, Huitema ADR, Kappelhoff BS, Meenhorst PL, Mulder JW, Prins JM, et al. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet. 2005;44:849-61.
26. Colombo S, Buclin T, Cavassini M, Décosterd LA, Telenti A, Biollaz J, et al. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2006;50:3801-8.
27. Jullien V, Tréluyer J-M, Rey E, Jaffray P, Krivine A, Moachon L, et al. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob Agents Chemother. 2005;49:3361-6.
28. Moore KHP, Yuen GJ, Hussey EK, Pakes GE, Eron JJ, Bartlett JA. Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob Agents Chemother. 1999;43:3025-9.
29. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19:716-23.
30. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481-504.
31. Bulitta J, Bingölbali A, Shin B, Landersdorfer C. Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS J. 2011;13:201-11.
32. Bulitta J, Landersdorfer C. Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models. AAPS J. 2011;13:212-26.
33. Okusanya OO, Hamel J, Rubino CM. SADAPTPlot - an easy-to-use R package for S-ADAPT population analysis post-processing [poster]. American Conference on Pharmacometrics; 2011 Apr 4-7; San Diego.
34. Gagnieu M-C, Barkil ME, Livrozet J-M, Cotte L, Miailhes P, Boibieux A, et al. Population pharmacokinetics of tenofovir in AIDS patients. J Clin Pharmacol. 2008;48:1282-8.
35. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3:112re4.
36. Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004;48:437-43.
37. Salas Herrera IG, Pearson RM, Turner P. Quantitation of albumin and alpha-1-acid glycoprotein in human cervical mucus. Hum Exp Toxicol. 1991;10:137-9.
38. Dumond JBP, Patterson KBMD, Pecha ALP, Werner REBS, Andrews EP, Damle BP, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr. 2009;51:546-53.
39. Bonnet B, Diquet B, Duval X, Goujard C, Katlama C, Legrand M, et al. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy. Clin Pharmacokinet. 2005;44:1267-78.
40. Nettles RE, Kieffer TL, Parsons T, Johnson J, Cofrancesco J Jr, Gallant JE, et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis. 2006;42:1189-96.
41. Zhu M, Kaul S, Nandy P, Grasela DM, Pfister M. Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. Antimicrob Agents Chemother. 2009;53:2346-53.